Emmetropia

Bausch + Lomb Announces the Presentation of New Scientific Data on Products and Pipeline Programs at the American Society of Cataract and Refractive Surgery Annual Meeting

Retrieved on: 
Wednesday, April 26, 2023

The posters and presentations include two studies assessing the new StableVisc™ cohesive ophthalmic viscosurgical device, which Bausch + Lomb commercially launched this month.

Key Points: 
  • The posters and presentations include two studies assessing the new StableVisc™ cohesive ophthalmic viscosurgical device, which Bausch + Lomb commercially launched this month.
  • Others include a retrospective chart review on the use of LOTEMAX® SM (loteprednol etabonate ophthalmic gel) 0.38% in refractive surgery and numerous presentations focused on Bausch + Lomb surgical IOL pipeline programs.
  • New data from the Bausch + Lomb Antibiotic Resistance Monitoring in Ocular micRoorganisms (ARMOR) surveillance study will also be presented.
  • “Clinical Evaluation of the Outcomes of Two Preloaded Monofocal IOLs Implanted Bilaterally in Cataract Patients.” Shultz et al.

SightMD NJ Surgeon performs first implantation of this revolutionary intraocular lens in New Jersey

Retrieved on: 
Tuesday, April 25, 2023

HAUPPAUGE, N.Y., April 25, 2023 /PRNewswire-PRWeb/ -- A dramatically New design IntraOcular Lens called the Apthera IC-8 was approved by the FDA and released in Jan of 2023 and we are excited to announce that the first implantation of this revolutionary intraocular lens in New Jersey was performed by SightMD Ophthalmic Surgeon Omar F. Almallah, MD last week.

Key Points: 
  • The IC-8 Apthera Intraocular Lens (IOL) is an artificial lens implanted in the eye of adult patients.
  • The lens is intended to provide vision correction after the eye's natural lens is removed because it has become cloudy (cataract).
  • The IC-8 Apthera IOL is the first small aperture lens that delivers extended depth of focus through its distinctive wavefront-filtering design.
  • The IC-8 Apthera lens is an extended depth of focus intraocular lens.

Johnson & Johnson Vision Introduces All Purpose EDOF, TECNIS Symfony OptiBlue IOL, the Latest PC-IOL Powered by InteliLight Technology

Retrieved on: 
Wednesday, September 28, 2022

IRVINE, Calif., Sept. 28, 2022 /PRNewswire/ -- Johnson & Johnson Vision,** a global leader in eye health and part of Johnson & Johnson MedTech,*** today announced availability of our presbyopia-correcting intraocular lens (PC-IOL) powered by InteliLight technology https://www.jnjvisionpro.com/intelilight, TECNIS Symfony OptiBlue IOL. This extended depth-of-focus (EDOF) lens expands presbyopia correction to more patients and joins TECNIS Synergy IOL, a high-performance hybrid lens designed for spectacle independence****, in the InteliLight portfolio. These two complementary products deliver superior* contrast and low-light performance across the PC-IOL category.1,2,3 The InteliLight portfolio will be on display at the 2022 American Academy of Ophthalmology's Annual Meeting (AAO) in Chicago, Sept. 30-Oct. 3.

Key Points: 
  • To learn more about the InteliLight portfolio, please visit https://www.jnjvisionpro.com/intelilight in the U.S.
    At Johnson & Johnson Vision, part of Johnson & Johnson MedTech**, we have a bold ambition: to change the trajectory of eye health worldwide.
  • Visit us at jjvision.com , follow @JNJVision on Twitter , Johnson & Johnson Vision on LinkedIn , and @JNJVision on Facebook .
  • Neither Johnson & Johnson Vision, the Johnson & Johnson MedTech Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.
  • **Johnson & Johnson Vision represents the products and services of Johnson & Johnson Surgical Vision, Inc., Johnson & Johnson Vision Care, Inc., and the affiliates of both.

Visus Therapeutics Initiates Phase 2 Clinical Trial of BRIMOCHOL for the Treatment of Presbyopia

Retrieved on: 
Thursday, March 25, 2021

Presbyopia is the loss of near vision associated with aging, making it difficult to perform certain tasks like reading fine print.

Key Points: 
  • Presbyopia is the loss of near vision associated with aging, making it difficult to perform certain tasks like reading fine print.
  • We have designed a robust clinical development program in a diverse population of patients living with presbyopia.
  • The Phase 2 clinical trial ( NCT04774237 ) is a double-masked, randomized crossover study designed to evaluate the safety and efficacy of two proprietary formulations of BRIMOCHOL topical ophthalmic solution in patients with emmetropic phakic and pseudophakic presbyopia.
  • With offices in Seattle and Orange County, Calif., its lead clinical candidate is BRIMOCHOL, an eye drop designed to correct the loss of near vision associated with presbyopia.

Spectacle Lens Designed by PolyU Slows Myopic Progression by 60% and Stops in 21.5% of Children

Retrieved on: 
Wednesday, April 18, 2018

This lens will be launched in summer this year, offering a non-contact, spectacle lens solution to myopic children.

Key Points: 
  • This lens will be launched in summer this year, offering a non-contact, spectacle lens solution to myopic children.
  • For spectacle lens, the challenge is the eye will move behind the spectacle lens and therefore the myopic defocus optics has to be incorporated all over the lens," said Professor To.
  • For the individual, in addition to slow myopic progression, the study shows that wearing DIMS Spectacle Lens stops the progression of myopia in some children.
  • 21.5% of children in the treatment group had no myopic progression whereas only 7.4% of children in the control group had no myopic progression.